Fresenius

Vifor Pharma Group Supports Rare Disease Day 2019

Retrieved on: 
Thursday, February 28, 2019
Health, Biotechnology, Clinical trials, Pharmaceutical, Research, Science, Health, Articles, Rare Disease Day, Vifor Pharma, Rare disease, European Organisation for Rare Diseases, Fresenius, Health care

The Vifor Pharma Group today announces its support of Rare Disease Day, joining patients and healthcare providers around the world to support a day that raises awareness of the impact that rare diseases have and highlights the need for a greater understanding of these debilitating conditions.

Key Points: 
  • The Vifor Pharma Group today announces its support of Rare Disease Day, joining patients and healthcare providers around the world to support a day that raises awareness of the impact that rare diseases have and highlights the need for a greater understanding of these debilitating conditions.
  • Rare Disease Day is coordinated on an international scale by the European Organisation for Rare Diseases (EURORDIS) and the National Organisation for Rare Disorders (NORD) in the US.
  • The Rare Disease Day 2019 slogan is Show Your Rare, Show You Care and is focused on Bridging health and social care to address the challenges people affected by these diseases face every day.
  • The Vifor Pharma Group holds a leading position in all its core business activities and consists of the following companies: Vifor Pharma; VFMCRP, a joint company with Fresenius Medical Care; Relypsa; and OM Pharma.

FTC Requires Fresenius Medical Care AG & KGaA and NxStage Medical, Inc. to Divest Bloodline Tubing Assets to B. Braun Medical, Inc. as a Condition of Merger

Retrieved on: 
Wednesday, February 20, 2019
Medicine, Clinical medicine, Membrane technology, Renal dialysis, Hemodialysis, Tubing, Dialysis, NxStage, Fresenius

Bloodline tubing sets are single-use plastic tube sets used during hemodialysis treatments.

Key Points: 
  • Bloodline tubing sets are single-use plastic tube sets used during hemodialysis treatments.
  • The complaint alleges that the acquisition as proposed would likely result in substantial competitive harm to consumers in the U.S. market for bloodline tubing sets used in hemodialysis treatment.
  • Fresenius and NxStage are two of only three significant suppliers of bloodline tubing sets used in open architecture hemodialysis machines in the United States.
  • The proposed settlement seeks to maintain competition in the U.S. market for bloodline tubing sets and requires Fresenius and NxStage to divest to B. Braun all assets and rights to research, develop, manufacture, market, and sell NxStages bloodline tubing sets.

FTC Requires Fresenius Medical Care AG & KGaA and NxStage Medical, Inc. to Divest Bloodline Tubing Assets to B. Braun Medical, Inc. as a Condition of Merger

Retrieved on: 
Wednesday, February 20, 2019
Medicine, Clinical medicine, Membrane technology, Renal dialysis, Hemodialysis, Tubing, Dialysis, NxStage, Fresenius

Bloodline tubing sets are single-use plastic tube sets used during hemodialysis treatments.

Key Points: 
  • Bloodline tubing sets are single-use plastic tube sets used during hemodialysis treatments.
  • The complaint alleges that the acquisition as proposed would likely result in substantial competitive harm to consumers in the U.S. market for bloodline tubing sets used in hemodialysis treatment.
  • Fresenius and NxStage are two of only three significant suppliers of bloodline tubing sets used in open architecture hemodialysis machines in the United States.
  • The proposed settlement seeks to maintain competition in the U.S. market for bloodline tubing sets and requires Fresenius and NxStage to divest to B. Braun all assets and rights to research, develop, manufacture, market, and sell NxStages bloodline tubing sets.

Fresenius Kabi Announces Inductees to Blood Donation Hall of Fame

Retrieved on: 
Tuesday, February 19, 2019
Health, Philanthropy, Other Philanthropy, General Health, Transfusion medicine, Fresenius, Societates Europaeae, Blood donation, Economy of Germany, Life sciences, Companies

Fresenius Kabi announced today it has inducted 12 people as the 2018 class of the Fresenius Kabi Blood Donation Hall of Fame, a nationwide program that recognizes and shares the unique stories of individuals from across the country who demonstrate commitment and passion for donating blood and encouraging blood donation.

Key Points: 
  • Fresenius Kabi announced today it has inducted 12 people as the 2018 class of the Fresenius Kabi Blood Donation Hall of Fame, a nationwide program that recognizes and shares the unique stories of individuals from across the country who demonstrate commitment and passion for donating blood and encouraging blood donation.
  • View the full release here: https://www.businesswire.com/news/home/20190219005226/en/
    Keith Olson is one of 13 people inducted this year into the Fresenius Kabi Blood Donation Hall of Fame.
  • For 20 years, Fresenius Kabi has worked shoulder-to-shoulder with blood centers, donors and volunteers to ensure that patients have access to blood.
  • Nominations for the 2019 Fresenius Kabi Donation Hall of Fame are due by June 14, 2019.

Global Renal Dialysis Equipment Market Report 2019: Analysis & Forecasts 2015-2024 with Industry Guide & Contact Details for 70 Companies

Retrieved on: 
Wednesday, February 13, 2019
Medicine, Clinical medicine, Membrane technology, Renal dialysis, Companies, Fresenius Medical Care, Fresenius, Hemodialysis, NxStage, Dialysis, Rockwell Medical

BD Completes the Acquisition of TVA Medical, Inc for its Dialysis Access Technology

Key Points: 
  • BD Completes the Acquisition of TVA Medical, Inc for its Dialysis Access Technology
    Fresenius Medical Care Reinforces its Vertically Integrated Dialysis Business by Acquiring NxStage Medical.
  • Inc
    Fresenius Medical Care Launches 6008, a New Hemodialysis Therapy System in the Asia-Pacific Market
    Nikkiso Launches DBB-06 Hemodialysis System in the U.S. Market

Fresenius Medical Care North America Launches 2008T BlueStar™ Hemodialysis Machine Across the U.S.

Retrieved on: 
Monday, February 11, 2019
Medicine, Clinical medicine, Membrane technology, Renal dialysis, Health, Hemodialysis, Fresenius Medical Care, Fresenius, Dialysis, Nephrology, Nathan W. Levin, Home hemodialysis

WALTHAM, Mass., Feb. 11, 2019 /PRNewswire/ --Fresenius Medical Care North America's Renal Therapies Group today announced market availability of the 2008T BlueStar hemodialysis machine .

Key Points: 
  • WALTHAM, Mass., Feb. 11, 2019 /PRNewswire/ --Fresenius Medical Care North America's Renal Therapies Group today announced market availability of the 2008T BlueStar hemodialysis machine .
  • "The new and enhanced 2008T BlueStar hemodialysis machines provide more than 30 unique enhancements to better serve end stage renal disease patients undergoing dialysis," said Mark Costanzo, President of Renal Therapies Group at Fresenius Medical Care North America.
  • "We believe our 2008T BlueStar machine offers distinct clinical advantages that streamline the complexities of hemodialysis care and enhance patients' overall treatment experience."
  • Fresenius Medical Care North America (FMCNA) is the premier healthcare company focused on providing the highest quality care to people with renal and other chronic conditions.

Fresenius Kidney Care Leads Industry in Patient Safety Program for Third Straight Year

Retrieved on: 
Thursday, January 31, 2019
Medicine, Clinical medicine, Membrane technology, Health, Renal dialysis, Fresenius, Societates Europaeae, Nephrology, Hemodialysis, Home hemodialysis, Dialysis, National Kidney Foundation

WALTHAM, Mass., Jan. 31, 2019 /PRNewswire/ --Fresenius Kidney Care, the dialysis division of Fresenius Medical Care North America and the nation's leading network of dialysis facilities, achieved industry-leading results from the 2018 5-Diamond Patient Safety Program for the third straight year.

Key Points: 
  • WALTHAM, Mass., Jan. 31, 2019 /PRNewswire/ --Fresenius Kidney Care, the dialysis division of Fresenius Medical Care North America and the nation's leading network of dialysis facilities, achieved industry-leading results from the 2018 5-Diamond Patient Safety Program for the third straight year.
  • Fresenius Kidney Care maintained its 5-Diamond status at 99.96 percent of its in-center and home hemodialysis programs, while 100 percent of enrolled Fresenius Kidney Care acute care dialysis centers achieved 5-Diamond status.
  • "Our top priority for every patient in our care is their safety," said Mike Asselta, President of Fresenius Kidney Care.
  • Fresenius Kidney Care will continue to participate in the 5-Diamond Patient Safety Program as part of its commitment to delivering an exceptional patient experience.

Fresenius Kabi Introduces Leucovorin Calcium Injection, USP

Retrieved on: 
Tuesday, January 29, 2019
Health, Pharmaceutical, Other Health, General Health, Drugs, Chemistry, Organic compounds, RTT, Folinic acid, Fresenius, Alcohols, Combination drugs, Conjugated estrogens

Fresenius Kabi announced today the immediate availability in the United States of Leucovorin Calcium Injection, USP, a medication indicated to counteract the toxicity and diminish the effects of impaired methotrexate elimination.

Key Points: 
  • Fresenius Kabi announced today the immediate availability in the United States of Leucovorin Calcium Injection, USP, a medication indicated to counteract the toxicity and diminish the effects of impaired methotrexate elimination.
  • View the full release here: https://www.businesswire.com/news/home/20190129005098/en/
    Fresenius Kabi introduces Leucovorin Calcium Injection, USP.
  • Fresenius Kabi Leucovorin Calcium Injection, USP is available in 10 mg per mL single-use vials, 100 mg per 10 mL and 500 mg per 50 mL strengths.
  • At Fresenius Kabi we are dedicated to finding safe and affordable solutions for health care providers, said John Ducker, president and CEO of Fresenius Kabi USA.

1 in 6 Outpatient Dialysis Patients with Acute Kidney Injury Lasting More Than 90 Days Still Recover Kidney Function, According to New Data from Fresenius Medical Care North America

Retrieved on: 
Thursday, January 24, 2019
Medicine, Medical specialties, Clinical medicine, Kidney diseases, Membrane technology, Fresenius Medical Care, Fresenius, Dialysis, Renal dialysis, Medicare, Acute kidney injury, Kidney

WALTHAM, Mass., Jan. 24, 2019 /PRNewswire/ -- Fresenius Medical Care North America (FMCNA), the nation's leading renal care company, announces preliminary results from an analysis of new data on more than 9,000 patients with acute kidney injury (AKI) treated at Fresenius Kidney Care outpatient dialysis centers.

Key Points: 
  • WALTHAM, Mass., Jan. 24, 2019 /PRNewswire/ -- Fresenius Medical Care North America (FMCNA), the nation's leading renal care company, announces preliminary results from an analysis of new data on more than 9,000 patients with acute kidney injury (AKI) treated at Fresenius Kidney Care outpatient dialysis centers.
  • Overall, 38 percent of individuals with AKI requiring outpatient dialysis treatment recovered kidney function within 150 days of initiating outpatient therapy.
  • Fresenius Medical Care began collecting this new data in 2017 after the Centers for Medicare and Medicaid Services (CMS) authorized outpatient dialysis centers to provide treatment for Medicare beneficiaries with AKI requiring dialysis.
  • Fresenius Medical Care North America (FMCNA) is the premier healthcare company focused on providing the highest quality care to people with renal and other chronic conditions.

CytoSorbents Announces Expansion of CytoSorb® Partnership with Fresenius Medical Care

Retrieved on: 
Tuesday, January 22, 2019
Companies, Fresenius, Societates Europaeae, Economy of Germany, Health, Acute care

Under the terms of the agreement, Fresenius Medical Care has the exclusive rights to distribute CytoSorb for acute care and other hospitalapplications in Korea and Mexico.

Key Points: 
  • Under the terms of the agreement, Fresenius Medical Care has the exclusive rights to distribute CytoSorb for acute care and other hospitalapplications in Korea and Mexico.
  • Mr. Alfredo Merino, Senior Vice President - Business Strategy of Fresenius Medical Care North America, and CEO Fresenius Medical Care Mexico, said, "We are excited to expand our partnership with CytoSorbents to introduce CytoSorb to the Mexican healthcare system.
  • Dr. Phillip Chan, CEO of CytoSorbents commented, "We are pleased to extend our collaboration with Fresenius Medical Care into these large and strategically important markets.
  • Fresenius Medical Care's expertise in intensive care and strong commercial organizations in Mexico and Korea make them an excellent partner for CytoSorb."